Children with Ewing’s Sarcoma Most Likely to Experience Late Recurrence
Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute.
As cancer treatment has improved and evolved, the number of survivors of childhood and adolescent cancers has increased; however, there is limited data regarding late recurrence of these cancers. Researchers performed a retrospective analysis of patients treated for pediatric cancer in order to evaluate patterns of late recurrence.
The review included data collected from 12,795 patients with no history of recurrence within the first five years of diagnosis. The median age at original diagnosis was 8.3 years; 806 patients experienced a recurrence five or more years after diagnosis.
The cumulative incidence of recurrence between five and 20 years was 6.2%. Survivors of astrocytoma had the highest 20-year cumulative incidence (14.4%), followed by survivors of Ewing’s sarcoma (13%). Survivors of kidney cancer had the lowest risk of recurrence after 20 years.
Zenocutuzumab - the first approved systemic therapy for patients with NRG1 fusion–positive NSCLC or pancreatic adenocarcinoma.
Zenocutuzumab targeted therapy approved for treatment of pancreatic ductal adenocarcinoma and non-small cell lung cancer with NRG1 fusions.
Immunotherapy After Chemoradiotherapy Promising in Limited-Stage Small Cell Lung Cancer
Adjuvant therapy with Imfinzi (durvalumab) significantly improved survival outcomes for patients with limited-stage SCLC
Breakthrough in Understanding Tamoxifen's Effectiveness in Breast Cancer: Gut Bacteria Play a Crucial Role
Since tamoxifen is taken orally and travels through the digestive system, variations in patient responses may be connected to the gut microbiome—the trillions of bacteria in our intestines that differ significantly from one person to another.
The researchers found that the greatest risk factors for late recurrence included diagnosis, combination treatment with chemotherapy and radiation, and earlier treatment era. They assert that late recurrence is a risk for some childhood cancers, yet the risk might be abated by being informed and remaining vigilant about follow-up.
Reference:
Wasilewski-Masker K, Liu Q, Yasui Y, et al. Late recurrence in pediatric cancer: A report from the Childhood Cancer Survivor Study. Journal of the National Cancer Institute. 2009; 101: 1709-1720.
Copyright © 2018 CancerConnect. All Rights Reserved.
